HOUSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) — Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that management will participate in the following upcoming investor conferences:
JonesTrading C-Suite Fireside Chat Series
Date: Wednesday, February 19, 2026
Time: 11:00 AM EST
Registration Link here
Oppenheimer 36
th
Annual Healthcare Life Sciences Conference
Format: Corporate presentation
Date: Wednesday, February 25, 2026
Time: 10:40 AM EST
Location: Virtual
TD Cowen 46
th
Annual Health Care Conference
Format: Corporate presentation
Date: Tuesday, March 3, 2026
Time: 1:50 PM EST
Location: Boston, MA
Barclays 28
th
Annual Global Healthcare Conference
Format: Fireside chat
Date: Tuesday, March 10, 2026
Time: 2:00 PM EST
Location: Miami Beach, FL
The webcast of the JonesTrading fireside chat and Oppenheimer presentation will be accessible on the Tvardi Investors’ website. A replay of the webcasts will be available for approximately 90 days following the conference.
About Tvardi Therapeutics
Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The company is conducting clinical trials with TTI-101 in hepatocellular carcinoma (NCT05440708) and TTI-109 in healthy volunteers. To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter).
Contacts:
For Tvardi:
Tvardi Investor Relations
[email protected]
PJ Kelleher
LifeSci Advisors
617-430-7579
[email protected]
